Circadian clock genes and risk of fatal prostate cancer

Cancer Causes and Control

Volumn 26, Issue 1, 2015, Pages 25-33

  Markt, Sarah C ^a   Valdimarsdottir, Unnur A ^a,b   Shui, Irene M ^a   Sigurdardottir, Lara G ^b,c   Rider, Jennifer R ^a,d   Tamimi, Rulla M ^a,d   Batista, Julie L ^a,d   Haneuse, Sebastien ^a   Flynn Evans, Erin ^d,e   Lockley, Steven W ^d,e   Czeisler, Charles A ^d,e   Stampfer, Meir J ^a,d   Launer, Lenore ^g   Harris, Tamara ^g   Smith, Albert Vernon ^b,f   Gudnason, Vilmundur ^b,f   Lindstrom, Sara ^a   Kraft, Peter ^a   Mucci, Lorelei A ^a,b,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ICELAND   (Iceland)

^c ICELANDIC CANCER SOCIETY   (Iceland)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f ICELANDIC HEART ASSOCIATION   (Iceland)

^g NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Circadian genes; Genetic polymorphisms; Prostate cancer

Indexed keywords

6 HYDROXYMELATONIN O SULFATE;

AGED; ARTICLE; CANCER RISK; CIRCADIAN RHYTHM; COHORT ANALYSIS; CONTROLLED STUDY; CRY1 GENE; CSNK1E GENE; FATALITY; GENE; GENETIC ASSOCIATION; GENETIC RISK; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NPAS2 GENE; PER3 GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TIMELESS GENE; CAUCASIAN; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; ICELAND; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR;

AGED; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; ICELAND; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84930928812     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0478-z     Document Type: Article

References (41)

1. Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3(5):350–361
2. Zhu Y et al (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case–control study. Cancer Res 69(24):9315–9322
3. Davis S, Mirick DK (2006) Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control 17:539–545
4. Blask DE (2009) Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 13(4):257–264
5. Costa G, Haus E, Stevens R (2010) Shift work and cancer—considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health 36(2):163–179
6. Buja A et al (2005) Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data. Toxicol Ind Health 21(10):273–282
7. Straif K et al (2007) Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 8(12):1065–1066
8. Parent ME et al (2012) Night work and the risk of cancer among men. Am J Epidemiol 176(9):751–759
9. Sigurdardottir LG et al (2014) Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. doi:10.1016/j.eururo.2014.07.008
10. Sigurdardottir LG et al (2012) Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 21:1002–1011
11. Sigurdardottir LG et al (2013) Sleep disruption among older men and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 22(5):872–879
12. Kondratov RV, Gorbacheva VY, Antoch MP (2007) The role of mammalian circadian proteins in normal physiology and genotoxic stress responses. Curr Top Dev Biol 78:173–216
13. Young MW, Kay SA (2001) Time zones: a comparative genetics of circadian clocks. Nat Rev Genet 2(9):702–715
14. Utge SJ et al (2010) Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance. PLoS One 5(2):e9259
15. Slominski RM et al (2012) Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 351(2):152–166
16. Antoch MP, Kondratov RV, Takahashi JS (2005) Circadian clock genes as modulators of sensitivity to genotoxic stress. Cell Cycle 4(7):901–907
17. Gauger MA, Sancar A (2005) Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res 65(15):6828–6834
18. Borgs L et al (2009) Cell “circadian” cycle: new role for mammalian core clock genes. Cell Cycle 8(6):832–837
19. Hua H et al (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97(7):589–596
20. DeBruyne JP, Weaver DR, Reppert SM (2007) CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci 10(5):543–545
21. Chu LW et al (2008) Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 11(4):342–348
22. Lin DW et al (2011) Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 20(9):1928–1936
23. Harris TB et al (2007) Age, gene/environment susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 165(9):1076–1087
24. Giovannucci E et al (2003) Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 12(2):84–89
25. Schumacher FR et al (2011) Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 20(19):3867–3875
26. Iceland S (2011) (cited 2014). http://www.statice.is/
27. Psaty BM et al (2009) Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Design of Prospective Meta-Analyses of Genome-Wide Association Studies From 5 Cohorts. Circ Cardiovasc Genet 2(1):73–80
28. Murphy RA et al (2013) Candidate gene association study of BMI-related loci, weight, and adiposity in old age. J Gerontol A Biol Sci Med Sci 68(6):661–666
29. Nalls MA et al (2011) Multiple loci are associated with white blood cell phenotypes. PLoS Genet 7(6):e1002113. doi:10.1371/journal.pgen.1002113
30. Li Y et al (2009) Genotype imputation. Annu Rev Genomics Hum Genet 10:387–406
31. Cochran WG (1954) The combination of estimates from different experiments Biometrics 10:101–129
32. Evangelou E, Ioannidis JPA (2013) Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet 14:379–389
33. Wu MC et al (2010) Powerful SNP-set analysis for case–control genome-wide association studies. Am J Hum Genet 86(6):929–942
34. Lin X et al (2011) Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies. Genet Epidemiol 35(7):620–631
35. Kelly MA et al (2012) Circadian gene variants and susceptibility to type 2 diabetes: a pilot study. PLoS One 7(4):e32670. doi:10.1371/journal.pone.0032670
36. Cao Q et al (2009) A role for the clock gene Per1 in prostate cancer. Cancer Res 69(19):7619–7625
37. Hoffman AE et al (2008) The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6:1461–1468
38. Zhu Y et al (2006) Does “clock” matter in prostate cancer? Cancer Epidemiol Biomarkers Prev 15(1):3–5
39. Carpen JD et al (2005) A single-nucleotide polymorphism in the 5′-untranslated region of the hPER2 gene is associated with diurnal preference. J Sleep Res 14(3):293–297
40. Evans DS et al (2013) Common genetic variants in ARNTL and NPAS2 and at chromosome 12p13 are associated with objectively measured sleep traits in the elderly. Sleep 36(3):431–446
41. Duffy JF, Wright KP (2005) Entrainment of the human circadian system by light. J Biol Rhythms 20:326–338